April 16th 2024
A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status
May 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, discussed results of the phase 3 PROpel trial of patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
Read More
Physicians Discuss When to Use a PARP Inhibitor in mCRPC
May 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, and participants discussed situations when they would use a PARP inhibitor to treat patients with metastatic castration-resistant prostate cancer in the second or third line. This is the first of 2 articles based on this event.
Read More
ODAC Decision for Olaparib/Abiraterone in mCRPC Likely to Impact Forthcoming Studies
May 12th 2023In an interview with Targeted Oncology™, Andrew J. Armstrong, MD gave a first-hand perspective on the discussion held during the recent ODAC meeting and explained what the discussion and vote mean for the future of olaparib plus abiraterone in metastatic castration-resistant prostate cancer.
Read More
Racial Disparities Linked With High Rates of ADT-Related AEs in Prostate Cancer
May 9th 2023Significant differences in the incidence of genitourinary events, depression, and ischemic and thrombotic events were observed based on race among patients with prostate cancer after receiving androgen deprivation therapy.
Read More
FDA's ODAC Votes Yes to Olaparib Combination Being Restricted to BRCAm mCRPC
April 28th 2023The Oncologic Drugs Advisory Committee has discussed the approval application for olaparib plus abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer and voted on its potential future.
Read More
Phase 1 Study Evaluates Combinations of EPI-7386 for Prostate Cancers
April 24th 2023A phase 1 trial of EPI-7386 will evaluate the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of the agent in combination with apalutamide or abiraterone acetate plus prednisone.
Read More
Roundtable Discussion: Zakharia Considers Next-Line Therapy Sequencing for mCRPC
April 17th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Yousef Zakharia, MD, discussed next-line therapy for a patient with metastatic castration-resistant prostate cancer who has received docetaxel and an androgen receptor–targeted therapy.
Read More
Higher Dose of Apalutamide for mCRPC and mCSPC Now Available in the United States
April 10th 2023A new apalutamide tablet has become available for oncologists in the United States who treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Read More
ARAMIS Reinforces Findings from ARASENS and Other Studies of Darolutamide in nmCRPC
April 4th 2023In an interview with Targeted Oncology, Neal D. Shore, MD, FACS, gave an overview of previous and updated findings from the ARAMIS trial for patients with nonmetastatic castration-resistant prostate cancer.
Read More
Enzalutamide/Leuprolide Extends MFS in nmHSPC With High-Risk Bochemical Recurrence
March 17th 2023The phase 3 EMBARK trial of enzalutamide plus leuprolide is the first to elicit a statistically significant improvement in metastasis-free survival in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Read More